Eisai Company, Ltd. Confirms Therapeutic Effects of Lenvatinib in Patients With Melanoma in Strategic Collaboration With Quintiles, Inc. to Develop Eisai Anticancer Compounds

Published: Jun 10, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Tokyo, June 10, 2013 (JCN Newswire) - Eisai Co., Ltd. announced today that the therapeutic effects of lenvatinib (generic name; VEGF receptor tyrosine kinase inhibitor and multi-kinase inhibitor discovered in-house) on melanoma have been confirmed in one of a series of joint development programs being conducted as part of the company's strategic collaboration with Quintiles (United States). The finding has provided the basis for the first proof of concept (POC) to be achieved under the partnership.

Help employers find you! Check out all the jobs and post your resume.

Back to news